A multicentre study to determine the efficacy of flomoxef against extended-spectrum beta-lactamase producing in Malaysia.

Background: The high burden of extended-spectrum beta-lactamase-producing (ESBL)-producing Enterobacterales worldwide, especially in the densely populated South East Asia poses a significant threat to the global transmission of antibiotic resistance. Molecular surveillance of ESBL-producing pathogens in this region is vital for understanding the local epidemiology, informing treatment choices, and addressing the regional and global implications of antibiotic resistance.

Methods: Therefore, an inventory surveillance of the ESBL- (ESBL-EC) isolates responsible for infections in Malaysian hospitals was conducted.

β-Lactam Resistance in Upper Respiratory Tract Pathogens Isolated from a Tertiary Hospital in Malaysia.

The rise of antimicrobial resistance (AMR) among clinically important bacteria, including respiratory pathogens, is a growing concern for public health worldwide. Common causative bacteria for upper respiratory tract infections (URTIs) include   and , and sometimes . We assessed the β-lactam resistant trends and mechanisms of 150 URTI strains isolated in a tertiary care hospital in Kuala Lumpur Malaysia.

In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing and Associated with Urinary Tract Infections in Malaysia.

The increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing has greatly affected the clinical efficacy of β-lactam antibiotics in the management of urinary tract infections (UTIs). The limited treatment options have resulted in the increased use of carbapenem. However, flomoxef could be a potential carbapenem-sparing strategy for UTIs caused by ESBL-producers.